EMIT II Plus Methadone AssayMonitor compliance with methadone treatment

The EMIT® II Plus Methadone Assay is intended for the qualitative and semiquantitative determination of methadone in human urine at a cutoff level of 150 ng/mL or 300 ng/mL. The assay does not detect the metabolite L-a-acetylmethadol (LAAM) at concentrations that would be found in the urine of patients on LAAM therapy.

Contact Us

Features & Benefits

Methadone is a synthetic analgesic for pain. It is frequently used in maintenance programs as a substitute for heroin or other abused opiates, while allowing the subject to successfully participate in drug rehabilitation. It suppresses opiate withdrawal symptoms, allowing the patients to function well and perform tasks competently. Recreationally, it is abused for its sedative and analgesic effect.

The EMIT II Plus Methadone Assay provides:

  • High parent specificity—ensures patient is compliant with methadone treatment
  • Identification of low-dose methadone patients at the 150 ng/mL cutoff
  • Excellent precision—all within-lab (total) CVs ≤1.7% or less across the assay range
  • Dual cutoffs available with one assay
  • Ready-to-use liquid reagents, calibrators, and controls
  • >95% correlation to reference method (GC/MS)


Applications are available for the Viva-Jr®, Viva-E®, Viva-ProE®, V-Twin® drug testing systems and AU® Series analyzers.

Technical Specifications

 Assay Principle

  Homogeneous Enzyme Multiplied Immonoassay (EMIT)


  150 ng/mL or 300 ng/mL



 Reagent Stability

  Unopened: until expiration date. Onboard instrument: up to 4 weeks

 Calibration Frequency

  As indicated by control results